Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Connect Biopharma and Neurogene, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
| Neurogene | 1 | 0 | 4 | 1 | 2.83 |
Connect Biopharma presently has a consensus target price of $6.86, indicating a potential upside of 534.92%. Neurogene has a consensus target price of $83.67, indicating a potential upside of 193.77%. Given Connect Biopharma’s higher possible upside, equities analysts clearly believe Connect Biopharma is more favorable than Neurogene.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 1,133.46 | -$55.48 million | ($1.19) | -0.91 |
| Neurogene | $930,000.00 | 612.78 | -$90.35 million | ($5.03) | -5.66 |
Connect Biopharma has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Connect Biopharma and Neurogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -165.41% | -121.58% |
| Neurogene | N/A | -45.10% | -41.00% |
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Connect Biopharma has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500.
Summary
Connect Biopharma beats Neurogene on 8 of the 14 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
